What is Merrimack Pharmaceuticals Financial Strength?
Merrimack Pharmaceuticals has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Merrimack Pharmaceuticals Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Merrimack Pharmaceuticals has no long-term debt (1).
As of today, Merrimack Pharmaceuticals's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Merrimack Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Merrimack Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merrimack Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Merrimack Pharmaceuticals's Financial Strength falls into.
Merrimack Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Merrimack Pharmaceuticals's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-0.49 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Merrimack Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is
| Merrimack Pharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Merrimack Pharmaceuticals Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Merrimack Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Merrimack Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
| Eric Andersen |
director, other: See Remarks |
1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404 |
| Gary L Crocker |
director, officer: President |
MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
| Noah G. Levy |
director, other: See Remarks |
60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165 |
| Ana Radeljevic |
director |
2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467 |
| Ulrik B. Nielsen |
director |
MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
| Russell T Ray |
director |
2525 DUPONT DR, IRVINE CA 92612 |
| Newtyn Capital Partners, Lp |
other: See Remarks |
60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
| Ledo Capital, Llc |
other: See Remarks |
60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
| Newtyn Te Partners, Lp |
other: See Remarks |
60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
| Newtyn Partners, Lp |
other: See Remarks |
60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
| Western Standard Partners Qp, L.p. |
other: See Remarks |
5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
| Western Standard Partners Lp |
other: See Remarks |
5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036 |
| Western Standard Llc |
other: See Remarks |
5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036 |
| Newtyn Management, Llc |
other: See Remarks |
60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165 |
| 22nw Gp, Inc. |
10 percent owner, other: See Explanation of Responses |
1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MACK has been successfully added to your